MA49599B1 - Anticorps spécifiques à cd47 et pd-l1 - Google Patents

Anticorps spécifiques à cd47 et pd-l1

Info

Publication number
MA49599B1
MA49599B1 MA49599A MA49599A MA49599B1 MA 49599 B1 MA49599 B1 MA 49599B1 MA 49599 A MA49599 A MA 49599A MA 49599 A MA49599 A MA 49599A MA 49599 B1 MA49599 B1 MA 49599B1
Authority
MA
Morocco
Prior art keywords
antibodies
relates
antibodies specific
antigen
field
Prior art date
Application number
MA49599A
Other languages
English (en)
Other versions
MA49599A1 (fr
Inventor
Timofey Aleksandrovich Nemankin
Kirill Vladimirovich Solovyev
Andrei Borisovich Ulitin
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA49599A1 publication Critical patent/MA49599A1/fr
Publication of MA49599B1 publication Critical patent/MA49599B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne le domaine de la biotechnologie et notamment le domaine des anticorps ou leurs fragments de liaison d'antigènes ainsi que leur utilisation. Elle concerne plus particulièrement des anticorps qui se lient spécifiquement à cd47 et pd-l1. L'invention concerne également un acide nucléique codant pour cet anticorps ou son fragment de liaison d'antigènes, un vecteur d'expression, un procédé de production d'anticorps et l'utilisation de ces anticorps et composition dans la thérapie du cancer.
MA49599A 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1 MA49599B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201791961A EA039662B1 (ru) 2017-10-03 2017-10-03 Антитела, специфичные к cd47 и pd-l1
PCT/EA2018/050001 WO2019068302A1 (fr) 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1

Publications (2)

Publication Number Publication Date
MA49599A1 MA49599A1 (fr) 2021-01-29
MA49599B1 true MA49599B1 (fr) 2023-05-31

Family

ID=65994976

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49599A MA49599B1 (fr) 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1

Country Status (21)

Country Link
US (1) US11840567B2 (fr)
EP (1) EP3693390A4 (fr)
JP (2) JP2020535839A (fr)
KR (1) KR102937863B1 (fr)
CN (1) CN111801352B (fr)
AR (1) AR113342A1 (fr)
AU (1) AU2018345458B2 (fr)
BR (1) BR112020006706A2 (fr)
CA (1) CA3078413A1 (fr)
CL (1) CL2020000919A1 (fr)
CO (1) CO2020004199A2 (fr)
EA (1) EA039662B1 (fr)
EC (1) ECSP20024555A (fr)
JO (1) JOP20200078B1 (fr)
MA (1) MA49599B1 (fr)
MX (1) MX2020004027A (fr)
PE (1) PE20210460A1 (fr)
PH (1) PH12020550214A1 (fr)
TW (1) TWI768129B (fr)
WO (1) WO2019068302A1 (fr)
ZA (1) ZA202002047B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913263SA (en) 2016-09-29 2020-03-30 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs and preparation methods thereof
WO2018090950A1 (fr) 2016-11-18 2018-05-24 北京韩美药品有限公司 Anticorps bispécifique de type structure d'anticorps naturel anti-pd -1/anti-her2 de forme hétérodimère et sa préparation
CA3084626A1 (fr) 2017-12-04 2019-06-13 Beijing Hanmi Pharmaceutical Co., Ltd. Anticorps bispecifique anti-pd-l1/anti-cd47 ayant une structure d'un anticorps naturel et sous forme d'un heterodimere, et preparation associee
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
CA3084518A1 (fr) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Anticorps a domaine unique et des variants de celui-ci diriges contre pd-1
WO2019153200A1 (fr) 2018-02-08 2019-08-15 北京韩美药品有限公司 Anticorps bispécifique de type structure d'anticorps naturel anti-pd -1/anti-her2 sous forme hétérodimère et sa préparation
EP3564263A1 (fr) * 2018-05-03 2019-11-06 Universitätsklinikum Hamburg-Eppendorf Protéines de fusion comprenant un vhh spécifique de marqueur de surface cellulair
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
CN113825774B (zh) * 2019-05-17 2024-07-30 南京金斯瑞生物科技有限公司 抗cd47/抗pd-l1多抗原结合蛋白及其使用方法
US20220251210A1 (en) * 2019-06-25 2022-08-11 Innovent Biologics (Suzhou) Co., Ltd. Formulation comprising anti-cd47/pd-l1 bispecific antibody, method for preparing same and use thereof
CN114072426B (zh) * 2019-07-08 2024-01-26 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用
CN121975011A (zh) * 2019-09-27 2026-05-05 北京烁星生物医药科技有限公司 单特异性和多特异性抗体
CN112745392B (zh) * 2019-10-30 2022-07-01 上海洛启生物医药技术有限公司 抗pd-l1/cd47双特异性抗体及其用途
JP7369297B2 (ja) * 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
CN115315445B (zh) * 2020-02-12 2024-07-12 上海诗健生物科技有限公司 一种靶向人cd47的单域抗体及其用途
CA3187850A1 (fr) 2020-08-04 2022-02-10 Bryan Glaser Agents de liaison a pd-l1 et leurs utilisations
WO2022057939A1 (fr) * 2020-09-21 2022-03-24 I-Mab Biopharma Co., Ltd. Composition pharmaceutique comprenant un anticorps cd47 et un inhibiteur de pd-1/pd-l1
KR20230079393A (ko) * 2020-09-28 2023-06-07 상하이 헨리우스 바이오테크, 인크. 항 cd47 항체 및 사용 방법
WO2022095970A1 (fr) * 2020-11-06 2022-05-12 百奥泰生物制药股份有限公司 Anticorps bispécifique et son utilisation
EP4253415A4 (fr) * 2020-11-12 2024-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Anticorps et son procédé de préparation
KR20230129482A (ko) * 2021-01-08 2023-09-08 베이징 한미 파마슈티컬 컴퍼니 리미티드 항pd-l1/항cd47 천연항체 구조 형태의 헤테로다이머이중특이성 항체 및 그 제조방법
BR112023016706A2 (pt) * 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
CN116917322A (zh) * 2021-02-19 2023-10-20 沙裴隆有限公司 针对pd-l1及cd47的双特异性单域抗体及其用途
BR112023016713A2 (pt) * 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
WO2022235127A1 (fr) * 2021-05-07 2022-11-10 주식회사 이뮨온시아 Anticorps bispécifique se liant spécifiquement à cd47 et pd-l1
EP4359445A4 (fr) * 2021-06-21 2025-07-02 Biocad Joint Stock Co Anticorps bispécifique isolé se liant de mani7re spécifique à cd47 et pd-l1
CN115702931A (zh) * 2021-08-06 2023-02-17 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在治疗疾病中的应用
CN118076644A (zh) * 2021-09-30 2024-05-24 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体
EP4475886A4 (fr) * 2022-02-09 2026-03-18 Exelixis Inc Agents de liaison multispécifiques et leurs utilisations
EP4527853A1 (fr) * 2022-05-19 2025-03-26 Shaperon Inc. Anticorps bispécifique à domaine unique humanisé dirigé contre pd-l1 et cd47 et son utilisation
AU2023315757A1 (en) * 2022-07-28 2025-02-13 Shenzhen Enduring Biotech , Ltd. Peg based anti-cd47/anit-pd-l1 bispecific antibody-drug conjugate
CN118255894A (zh) * 2022-12-27 2024-06-28 广东菲鹏制药股份有限公司 一种双特异性结合分子及其应用
CN116063526B (zh) * 2022-12-31 2025-03-25 合肥天港免疫药物有限公司 抗pdl1的抗体及其用途
WO2024146539A1 (fr) * 2023-01-04 2024-07-11 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps bispécifiques dirigés contre pd-l1 et cd47, leur procédé de préparation et leur utilisation
IL328540A (en) * 2023-12-22 2026-07-01 Numab Therapeutics AG Antibody binding complexes specific for LILRB2
EP4574844A1 (fr) * 2023-12-22 2025-06-25 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour cd47 et pdl1
WO2025140478A1 (fr) * 2023-12-29 2025-07-03 百奥泰生物制药股份有限公司 Utilisation d'un anticorps bispécifique anti-pd-l1/cd47 en polythérapie

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0739904A1 (fr) 1989-06-29 1996-10-30 Medarex, Inc. Réactifs bispécifiques pour le traitement du SIDA
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2226962A1 (fr) 1998-02-16 1999-08-16 Marie Sarfati Utilisation d'agents liants a cd47 et ces ligands pour le traitement ou prophylaxie de maladies inflammatoire, autoimmunitaire et allergique et pour le traitement de rejet de greffons
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
WO2002016846A1 (fr) 2000-08-18 2002-02-28 Linde Aktiengesellschaft Procede de production d'un systeme de separation d'air
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (fr) 2009-11-24 2020-02-12 MedImmune Limited Agents de liaison ciblés contre b7-h1
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
ME03512B (fr) 2012-02-06 2020-04-20 Inhibrx Inc Anticorps anti-cd47 et leurs méthodes d'utilisation
RU2693078C2 (ru) * 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
GB201300706D0 (en) 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2016023001A1 (fr) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Agents pd-1 à haute affinité multispécifiques et procédés d'utilisation
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
RU2665790C1 (ru) * 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1

Also Published As

Publication number Publication date
RU2020115122A3 (fr) 2021-10-29
CA3078413A1 (fr) 2019-04-11
CO2020004199A2 (es) 2020-04-24
KR102937863B1 (ko) 2026-03-12
AU2018345458B2 (en) 2025-12-04
EP3693390A4 (fr) 2021-11-03
ECSP20024555A (es) 2020-06-30
ZA202002047B (en) 2022-08-31
TW201922781A (zh) 2019-06-16
US20200270345A1 (en) 2020-08-27
AR113342A1 (es) 2020-04-22
NZ763865A (en) 2025-05-30
EP3693390A1 (fr) 2020-08-12
US11840567B2 (en) 2023-12-12
BR112020006706A2 (pt) 2020-10-06
TWI768129B (zh) 2022-06-21
AU2018345458A2 (en) 2020-05-21
JOP20200078A1 (ar) 2020-04-30
EA201791961A1 (ru) 2019-04-30
PH12020550214A1 (en) 2021-02-15
EA039662B1 (ru) 2022-02-24
JP7676474B2 (ja) 2025-05-14
JP2023130455A (ja) 2023-09-20
JP2020535839A (ja) 2020-12-10
MA49599A1 (fr) 2021-01-29
KR20200058542A (ko) 2020-05-27
CN111801352A (zh) 2020-10-20
CN111801352B (zh) 2025-01-14
AU2018345458A1 (en) 2020-05-14
RU2020115122A (ru) 2021-10-29
PE20210460A1 (es) 2021-03-08
MX2020004027A (es) 2020-08-13
CL2020000919A1 (es) 2020-10-16
JOP20200078B1 (ar) 2024-04-17
WO2019068302A1 (fr) 2019-04-11

Similar Documents

Publication Publication Date Title
MA49599A1 (fr) Anticorps spécifiques à cd47 et pd-l1
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
MA49038B1 (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
MA39378A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
MX2009006891A (es) Anticuerpos cd44.
MA44547A1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
MA47221A1 (fr) Anticorps monoclonal à pd-l1
AU2017236063A1 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
MA54969A1 (fr) Anticorps monoclonal se liant spécifiquement à gitr
MA44207B1 (fr) Immunoglobulines conjuguées cys80
JOP20210159A1 (ar) أجسام مضادة لـ pmel17 ومترافقات منها
MA49607A1 (fr) Anticorps monoclonal pour il-5ra
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
MA43600B2 (fr) Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire
EA202092672A1 (ru) Антитела против dll3 и их применения
EA202092981A1 (ru) Антитела к l1cam и их применение
MA41666B1 (fr) Anticorps anti-ox40 et leurs utilisations
MA40086A1 (fr) Anticorps anti-vasa et leurs procédés de production et d'utilisation